Liu Peng, Han Zhong Chao
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China.
Int J Hematol. 2003 Jul;78(1):32-9. doi: 10.1007/BF02983237.
Acute promyelocytic leukemia (APL) is now the most potentially curable subtype of acute myeloid leukemia in adults because of the introduction of novel approaches in the management of this disease. All-trans-retinoic acid (ATRA)-based therapy is now the first-choice treatment of patients presenting with de novo APL, and clinical studies have shown that nearly all patients who receive ATRA therapy achieve complete remission. However, approximately 20% to 30% of APL patients eventually have relapses with resistance to further ATRA treatment. Arsenic trioxide (As2O3 [ATO]) has been established as highly effective therapy for patients with APL, even for those with disease refractory to ATRA. Furthermore, results of recent studies have suggested a broad therapeutic potential for ATO in the treatment of hematologic malignancies beyond APL. In this review, we discuss the clinical activity and multiple mechanisms of ATO therapy in the management of APL and other hematologic neoplasms.
由于在急性早幼粒细胞白血病（APL）的治疗中引入了新方法，它现已成为成人急性髓系白血病中最具潜在治愈可能的亚型。基于全反式维甲酸（ATRA）的疗法目前是初发APL患者的首选治疗方法，临床研究表明，几乎所有接受ATRA治疗的患者都能实现完全缓解。然而，约20%至30%的APL患者最终会复发，且对进一步的ATRA治疗产生耐药。三氧化二砷（As2O3 [ATO]）已被确立为治疗APL患者的高效疗法，即使是对ATRA难治的患者。此外，近期研究结果表明，ATO在治疗APL以外的血液系统恶性肿瘤方面具有广泛的治疗潜力。在本综述中，我们讨论了ATO疗法在APL和其他血液肿瘤治疗中的临床活性及多种作用机制。
